Why this comparison matters
Hims, Ro, and Mochi Health are three of the most-searched telehealth GLP-1 programs in 2026. All three let you get a prescription online without visiting a clinic. But their approaches differ in ways that matter — pricing structures, which drugs they actually prescribe, how much clinical support you get, and whether they accept insurance.
This guide compares them on the dimensions real patients care about most so you can shortlist without scheduling three separate consultations.
Medications offered
Hims primarily prescribes compounded semaglutide — a 503A pharmacy version of the active ingredient in Ozempic and Wegovy. As of early 2026, Hims does not prescribe brand-name Wegovy or Zepbound through its main weight loss program. Compounded medications are not FDA-approved for weight loss and are made by compounding pharmacies under different regulatory oversight than brand manufacturers.
Ro (Ro Body) prescribes both brand-name GLP-1s (Wegovy, Zepbound, Ozempic off-label) and compounded semaglutide. Which you get depends on your insurance, clinical profile, and what's in stock. Ro's flexibility here is a real advantage — if you have insurance that covers Wegovy, they can route you to the brand product.
Mochi Health focuses on compounded semaglutide and compounded tirzepatide. Mochi was one of the first to offer compounded tirzepatide (the active ingredient in Zepbound and Mounjaro), giving patients access to a dual-agonist even without insurance coverage for the brand product.
Pricing comparison
All prices below reflect the self-pay (no insurance) cost as of April 2026. Prices change frequently.
Hims: Starts around $199/month for compounded semaglutide. Pricing includes the medication, provider consultations, and shipping. Hims sometimes runs promotional pricing for new patients.
Ro Body: Starts around $99/month for the program fee, with medication cost varying. Compounded semaglutide through Ro typically runs $145–$300/month depending on dose. Brand-name drugs are billed through insurance when covered. Total out-of-pocket for self-pay patients can range from $250–$450/month.
Mochi Health: Plans start around $175/month for compounded semaglutide and $225/month for compounded tirzepatide. Mochi's pricing is relatively transparent and includes provider visits and medication.
Clinical depth
This is where the programs diverge most.
Hims takes a streamlined approach. The initial consultation is asynchronous (a questionnaire reviewed by a provider). Ongoing support is primarily through messaging. If you're someone who wants minimal friction — fill out a form, get your prescription, auto-refill monthly — Hims delivers. However, if you want in-depth clinical conversations about dose adjustments, lab interpretation, or comorbidity management, you may find the experience thin.
Ro Body offers a middle ground. You get a synchronous video consultation with a licensed provider, and Ro's platform integrates with at-home lab testing. They'll monitor metabolic markers over time. The provider relationship feels more substantive than Hims, though it's still telehealth — not a long-term PCP relationship.
Mochi Health positions itself as the most clinically intensive of the three. Visits are with obesity-trained providers (some are obesity medicine board-certified). Mochi tracks body composition, not just scale weight, and adjusts protocols based on lean mass retention. If you're concerned about muscle loss or want your provider to deeply understand GLP-1 pharmacology, Mochi is the strongest on clinical depth.
Insurance support
Hims: Self-pay only for GLP-1 weight loss. No insurance billing.
Ro Body: Accepts insurance for brand-name GLP-1s where coverage exists. Self-pay for compounded formulations.
Mochi Health: Primarily self-pay. Some plans offer insurance navigation assistance, but the core program is out-of-pocket.
Who each program is best for
Choose Hims if you want the simplest, most friction-free path to a compounded semaglutide prescription and don't need extensive clinical guidance. Best for healthy adults with straightforward weight loss goals.
Choose Ro if you want the flexibility to use insurance for brand-name GLP-1s, or if you value having a video-based provider relationship with integrated lab monitoring.
Choose Mochi if clinical depth matters most — you want a provider who specializes in obesity medicine, you're concerned about muscle loss, or you want access to compounded tirzepatide.
What about switching?
Switching between programs is straightforward in most cases. Your medical records are yours — you can request them from any provider. The main friction points are:
- Dose continuity: Make sure your new provider knows your
current dose and titration history.
- Compounded vs. brand: If you switch from compounded to
brand (or vice versa), your provider should re-titrate from a clinically appropriate starting point.
- Prescription timing: Plan a 2–3 week overlap to avoid
gaps in medication.
Our bottom line
There's no universally "best" program — it depends on what you're optimizing for. Hims wins on simplicity and price. Ro wins on flexibility (brand + compounded, insurance + self-pay). Mochi wins on clinical depth and access to compounded tirzepatide.
If budget is the primary constraint, start with Hims. If you have insurance that might cover Wegovy or Zepbound, start with Ro. If you want the most medically intensive experience and are willing to pay for it, start with Mochi.